Table 4 Patient outcomes.
From: Suppressed renoprotective purines in COVID-19 patients with acute kidney injury
No AKI | AKI | P-value | |
|---|---|---|---|
Sample size | 23 | 21 | |
30-day mortality | |||
Survived (%) | 19 (82.6) | 10 (47.6) | < 0.05 |
Died (%) | 4 (17.4) | 11 (52.4) | |
90-day mortality | |||
Survived (%) | 17 (73.9) | 10 (47.6) | 0.08 |
Died (%) | 6 (26.1) | 11 (52.4) | |
Discharged to: | |||
Home (%) | 9 (52.9) | 4 (40.0) | 0.5 |
Hospitalization (%) | 1 (5.9) | 0 (0.0) | |
Long term acute care (%) | 3 (17.6) | 1 (10.0) | |
Skilled nursing facility (%) | 4 (23.5) | 5 (50.0) | |
